Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bausch & Lomb Licenses Drugs

December 5, 2005 | A version of this story appeared in Volume 83, Issue 49

Bausch & Lomb has signed separate licensing agreements with Cephalon and PTC Therapeutics to develop small-molecule antiangiogenesis compounds for use in ophthalmology. Under the deal with Cephalon, Bausch & Lomb will develop Cephalon's VEGF inhibitor compounds, making milestone payments upon filing of a New Drug Application and royalties on future sales. PTC's antiangiogenesis program is based on its Gene Expression Modulation by Small Molecules technology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.